Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, predicted that though Trump had spared the industry with tariffs, that wouldn't last much longer.

Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves. Qatar pushes back on reports of $400M Boeing jet gift to Trump

The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult diseases.

The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the workforce-talent pipeline.

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%). It is the most valuable healthcare company in the world, with a market cap of around $800 billion. And yet it may still not be too late to invest in it.

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an overreaction to GLP-1 news.

The new research and development site will combine research, process development and clinical trial manufacturing capabilities into one plant.

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation and workforce development.

Lilly's weekly prescription data for Zepbound is up 354% year-over-year, while Novo's Wegovy is up just 61%. That's based on the latest prescription tracking data by analytics firm IQVIA, which shows total prescriptions for Wegovy at 211,103 in the week of April 18, and Zepbound totaling 338,899 prescriptions in the same week.

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP ...

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.